Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.18%
#3 CoW Protocol CoW Protocol +44.40%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +26.78%
#6 Walrus Walrus +24.24%
#7 Codatta Codatta +19.91%
#8 Enso Enso +18.69%
#9 Collector Crypt Collector Crypt +14.14%
#10 The Black Bull The Black Bull +13.35%
Coin of the day
EXOD EXOD
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Rang in aandelen #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Aandeelprijs
$0.117
Laatst gesynchroniseerd: 2025-04-04
Marktkapitalisatie
$2.45M
Verandering (1 dag)
-13.59%
Verandering (1 jaar)
0.00%
Land
US
Handel Carmell Therapeutics Corporation (CTCX)

Categorie

Healthcare
Winst voor Carmell Therapeutics Corporation (CTCX)
Winst in Jun 2026 TTM: $-6.79M
Volgens de meest recente financiële verslagen van Carmell Therapeutics Corporation bedraagt de huidige winst van het bedrijf $-6.79M. In 2023 behaalde het bedrijf een winst van $-16.21M, een daling ten opzichte van de winst van 2022, die $-9.05M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Carmell Therapeutics Corporation van 2021 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-6.79M -36.81%
2024 $-10.75M -33.68%
2023 $-16.21M 79.04%
2022 $-9.05M 2,647.97%
2021 $-329.38K 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -77,766.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -28,821.01%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -44,355.62%
BE